Xenetic Biosciences is trading 9.83% higher at $1.90, with no direct catalyst for the gain confirmed. - No new company-specific announcement dated October 27 was identified. - The latest company release located was the October 15 report that the first patient had been dosed in a collaborative study. - A biotech-sector rally is a possible influence, but it has not been confirmed as the reason for the stock’s move.